Drugs / BCL-2 indibitor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07573670 | May 2026 → Dec 2027 expected | mixed phenotype acute leukemia | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCL-2 indibitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07573670 ↗ |
| Action | Inhibit | “Bcl-2 inhibitor” NCT07573670 ↗ |
| Route | Oral | “Sonrotoclax:40mg qd (D1), 80mg qd (D2), 160mg qd (D3), 320mg qd (D4-D21), oral” NCT07573670 ↗ |
| Target | BCL2 | “Bcl-2 inhibitor” NCT07573670 ↗ |